1644.0000 -12.00 (-0.72%)
NSE Sep 22, 2025 15:31 PM
Volume: 1.8M
 

1644.00
-0.72%
Prabhudas Lilladhar
Taro's revenue was sequentially flattish while gross profit and gross margin were lower QoQ indicating continual price erosion, unfavorable product mix and impact from COVID. We expect sales growth to be muted and quarterly revenue to remain stable in the range of US$140-150m. Key event for Taro in the near-term would be utilization of US$1.55bn cash and cash equivalent for...
Sun Pharmaceutical I.. has an average target of 2050.25 from 8 brokers.
More from Sun Pharmaceutical Industries Ltd.
Recommended